Harvian puolivuosikatsaus 1. tammikuuta – 30. kesäkuuta 2026

Harvia Q2 2026 revenue rose 11.7% to €52.8m (vs. €47.3m), with Q2 adjusted operating profit up 4.8% to €8.6m (margin 16.2%). For 1H26, revenue increased 12.2% to €111.4m and adjusted operating profit rose 6.8% to €21.4m, with operating free cash flow up to €15.1m. The main drag was a major IT/process rollout at the Muurame factory and HQ that shifted ~€4m of deliveries and related margin into Q3, while North America grew 38.6% and management expects full operational capacity by the next quarter.

Analysis

The key read-through is not the headline growth, but the quality of that growth: North America is becoming the valuation driver, while Europe is temporarily being held back by execution timing rather than demand collapse. That matters because a regional mix shift toward the US should support a higher multiple if it proves durable, but the market will quickly discount it if Q3 only reflects shipment catch-up rather than true sell-through.

The near-term setup is favorable, but only for patient holders. The operational reset should mechanically lift reported growth and margins over the next 1-2 quarters as deferred revenue converts, yet the steam category weakness and Middle East project delays are reminders that not all end-markets are participating. If those two weak spots persist into H2, this becomes a narrower North America story with lower resilience than the stock deserves on a full-year basis.

Balance-sheet risk is not the issue; the equity risk is multiple compression if investors decide the growth rate is being padded by timing. The contrarian view is that the market may be underestimating how much the US channel expansion can sustain 2-3 year compound growth, but it may be overestimating how fast the rest of the portfolio re-accelerates. The decisive falsifier is a weak Q3 despite normalized operations, which would imply demand is softer than management is signaling.

Key Decisions for Investors

• Long HRVFF into the next 1-3 months on any post-print weakness; thesis is a Q3 catch-up quarter plus improving North America mix. Risk/reward is attractive as long as Q3 revenue and margin recover sequentially; reduce if deferred shipments do not show up.
• If you need a hedge, pair a modest long HRVFF with a short in broad discretionary exposure via XLY over the next 1-2 quarters. The goal is to isolate the secular wellness adoption story from a consumer-spending slowdown; cover the short if US consumer data improves and Harvia keeps comping above market.
• Set a watch alert for Q3 revenue and gross margin: if reported growth comes in only around H1 run-rate after the operational reset, treat the story as timing noise and not a demand inflection. That would be the signal to fade strength rather than add.
• No options trade unless liquidity is confirmed; this is a small-cap name where implied vol can overprice the event. Use cash equity sizing instead of calls/puts unless you can source tight spreads.